Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
暂无分享,去创建一个
Guan-Tarn Huang | Sheng-Nan Lu | Chien-Jen Chen | Hwai I. Yang | Sheng-Nan Lu | C. Jen | S. You | U. Iloeje | Guan-Tarn Huang | Chien-Jen Chen | San-Lin You | Hwai-I Yang | Jun Su | Uchenna H Iloeje | Chin-Lan Jen | Jun Su
[1] Ding‐Shinn Chen,et al. Hepatitis B Virus Infection , 2007 .
[2] O. Aalen. Nonparametric Inference for a Family of Counting Processes , 1978 .
[3] Chien-Jen Chen,et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. , 2005, Journal of the National Cancer Institute.
[4] A. Alberti. Can serum HBV‐DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B? , 2003, Hepatology.
[5] Chien-Jen Chen,et al. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: Multistage hepatocarcinogenesis with multifactorial etiology , 2002, Hepatology.
[6] N. Breslow,et al. A Large Sample Study of the Life Table and Product Limit Estimates Under Random Censorship , 1974 .
[7] Chien-Jen Chen,et al. Epidemiology of hepatitis B virus infection in the Asia–Pacific region , 2000, Journal of gastroenterology and hepatology.
[8] A. Lok,et al. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection , 2002, Hepatology.
[9] Dirk M. Hentschel. Troponin T levels and acute coronary syndromes. , 2002, The New England journal of medicine.
[10] B. McMahon,et al. Chronic hepatitis B , 2001, Hepatology.
[11] C. Gartung,et al. Antiviral therapy in HBe‐Ag–positive hepatitis B with normal aminotransferase levels , 2003, Hepatology.
[12] Chien-Jen Chen,et al. Epidemiological characteristics and risk factors of hepatocellular carcinoma , 1997, Journal of gastroenterology and hepatology.
[13] R. Beasley. Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.
[14] H. Hsu,et al. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: With special emphasis on the clearance of hepatitis B e antigen before 3 years of age , 1995, Hepatology.
[15] C. Gartung,et al. Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. , 2002, The New England journal of medicine.
[16] Y. Liaw,et al. Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update * , 2003, Journal of gastroenterology and hepatology.
[17] Chien-Jen Chen,et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.
[18] H. Hsu,et al. Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children , 1990, Hepatology.
[19] Chien-Jen Chen,et al. Seropositivity of hepatitis B e antigen and hepatocellular carcinoma , 2004, Annals of medicine.
[20] F. Rousseau,et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature , 2003, Hepatology.
[21] V. Rohatgi,et al. Small sample and efficiency results for the Nelson-Aalen estimator , 1993 .